Suzanne Bruhn, Ph.D. most recently served as president and CEO of Proclara Biosciences, a privately held, clinical-stage company pioneering a novel approach to treat disorders of protein misfolding including Alzheimer’s and Parkinson’s Disease, as well as orphan amyloidoses. Prior that that she served as president and CEO of Promedior, Inc., a privately held, clinical-stage immunotherapy company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. There, she successfully negotiated an exclusive agreement with Bristol Myers Squibb for the right to acquire Promedior for a total deal potential of $1.25 billion. Prior to Promedior, she spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire PLC, specializing in the development and commercialization of treatments for orphan diseases, where she held a series of positions of increasing responsibility before serving as senior vice president of strategic planning and program management. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs. She played a key role in the development, registration and global expansion of Shire HGT’s products, and in portfolio expansion through licensing and acquisitions. Prior to her time at HGT, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company.
Dr. Bruhn currently sits on the board of directors of Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), and of Novelion Therapeutics (NASDAQ: NVLN). She was formerly on the board of directors of Raptor Pharmaceuticals (NASDAQ: RPTP), until its acquisition by Horizon Pharma plc (NASDAQ:HZNP).
Dr. Bruhn holds a Bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.